Why Diet and Exercise Still Matter With GLP-1 Therapy

Science by Landon Deru, PhD, MBA, ATC

Part 1 of this series looked at how GLP-1 and related incretin medications work, how much weight people typically lose, and the fact that a meaningful share of that lost weight, roughly a quarter to nearly 40%, can come from lean tissue rather than fat. So, we will pick up where we left off to discuss why diet and exercise remain essential during treatment, internationally recognized physical activity recommendations, and what happens when people rely on medication alone.

What Exercise Does That Medication Doesn’t

GLP-1 therapy primarily changes hunger, satiety, and eating behavior. Exercise works through an entirely different set of pathways, producing adaptations in skeletal muscle, bone, insulin sensitivity, and metabolic flexibility that pharmacotherapy simply does not replicate^{[1] [2]}. Physical activity also improves cardiometabolic, cognitive, psychological, and mobility outcomes independent of weight loss, which is why focusing only on the scale is too narrow a way to measure success^{[1] [3]}. In fact, one of the strongest predictors of health and risk for death is your overall cardiorespiratory fitness. A smaller body is not automatically a healthier one if muscle function, fitness, or diet quality decline along the way^[3].

The Evidence for a Hybrid Approach

This isn’t just a theoretical argument. In a randomized trial that followed diet-induced weight loss, adding structured exercise to the GLP-1 drug liraglutide improved stair-climbing performance and cardiorespiratory fitness compared with liraglutide alone, while liraglutide by itself did not improve physical fitness at all^[4]. A related trial from the same research program found that combining exercise with a GLP-1 receptor agonist produced better maintenance of body weight and fat mass after stopping the medication, compared with either exercise or medication alone ^[5]. Taken together, this evidence is why current reviews increasingly describe a hybrid approach, medication combined with structured exercise and dietary counseling, as the most promising long-term framework, since the two appear additive and may help blunt regain after treatment ends ^{[6] [1]}.

The Guidelines: What to Actually Aim For

The American College of Sports Medicine’s (ACSM) core message for adults is simple to state and worth repeating: sit less and move more throughout the day, and build up to a minimum weekly dose of structured activity ^{[7] [8]}. Here is what they recommend:

ACSM Recommendation	What It Looks Like
Sit less, move more	Reduce total sedentary time throughout the day. Any amount of light movement in place of sitting has measurable health benefits, even before you get to structured exercise.
Aerobic activity	At least 150 minutes per week of moderate-intensity activity (e.g., brisk walking), or 75 minutes per week of vigorous-intensity activity, or an equivalent combination. More (up to 300 minutes) provides additional benefit.
Resistance training	A minimum of 2 days per week of muscle-strengthening activity covering all major muscle groups, at moderate or higher intensity.

These targets aren’t arbitrary. They are the threshold at which most of the measurable health benefits of physical activity, cardiovascular, metabolic, and musculoskeletal, begin to show up consistently across the population^[7]. For anyone on a GLP-1 medication, resistance training is the single most important piece of that prescription, because it is the clearest strategy currently available for preserving lean mass and physical function while the medication is driving a calorie deficit ^{[9] [10] [11]}. Adequate protein intake supports this, but protein alone, without exercise, is not enough ^{[11] [12] [13]}.

A Practical Care Pathway

Bringing this together, most expert reviews converge on a similar sequence of care:

Situation	Evidence-Based Course	Rationale
Before starting medication	Begin with a patient-centered assessment of diet, activity, strength, body composition, sleep, mental stress, and comorbidities.	GLP-1 therapy works best when prescribed into a lifestyle structure, not a lifestyle vacuum.
During active treatment	Continue calorie-aware eating, prioritize protein adequacy, and include structured aerobic plus resistance training per ACSM guidelines.	These are the most practical evidence-based strategies for preserving lean mass and function.
If side effects limit intake	Address GI symptoms and reduced food intake early with nutrition support rather than simply eating less.	Appetite suppression plus nausea can reduce protein and micronutrient intake.
If treatment stops	Maintain close follow-up and repeat lifestyle support to reduce regain.	Weight regain after discontinuation is common and often rapid.

What Happens If You Stop

The strongest argument against relying on medication alone is durability. Across systematic reviews, stopping GLP-1 therapy leads to meaningful regain in weight, waist circumference, blood glucose, and blood pressure, even when people continue receiving lifestyle advice ^{[14] [15] [16]}. One meta-analysis found average regain of 2.20 kg after stopping liraglutide and 9.69 kg after stopping semaglutide or tirzepatide ^[14], while another found average regain of 5.63 kg along with a 0.25% worsening in HbA1c after discontinuation ^{[15] [17]}.

Long-term use is also limited by real-world feasibility. Gastrointestinal side effects, nutrient inadequacy from reduced intake, cost, and access problems all contribute to high discontinuation rates, with some datasets reporting that 50% to 75% of users are off treatment within a year ^{[9] [18]}. This is exactly why the World Health Organization states plainly that medication alone cannot solve the obesity burden and calls for equitable, person-centered systems that combine behavioral, medical, and other interventions ^[19].

Common Assumptions, Checked Against the Evidence

Common Assumption	What the Evidence Shows
“The drug is enough if it suppresses appetite.”	Appetite suppression does not reproduce exercise’s effects on muscle, fitness, insulin sensitivity, or bone. Weight-loss quality matters, not just the number on the scale.
“I can stop once I reach my goal.”	Discontinuation commonly leads to regain, often proportional to the amount initially lost, because obesity behaves as a chronic disease.
“Lifestyle changes don’t work anyway.”	Lifestyle change is genuinely hard to sustain, but it still improves metabolic syndrome, blood pressure, lipids, glucose, physical function, and quality of life independent of weight lost.

Putting It All Together

The most honest, evidence-based way to think about GLP-1 medications is as a tool that reduces biological obstacles to weight loss, not as a substitute for the foundation that protects muscle, preserves function, and sustains health benefits over the long run ^{[6] [19]}. That foundation is diet quality, adequate protein, and physical activity built around the ACSM guidelines: sit less, move more, aim for at least 150 minutes of moderate-intensity aerobic activity a week, and don’t skip resistance training at least two days a week ^{[7] [8]}.

Personal decisions about starting, continuing, or stopping any weight management medication should be made with a licensed clinician who can account for your comorbidities, risks, and the support you will need for lasting results ^{[19] [6]}.

References

1. 1. Jakicic J, Behrens C, Deemer SE, et al. Physical activity and exercise within the context of obesity treatment: Enhancing health beyond weight loss. Journal of Sport and Health Science. 2025;15. doi:10.1016/j.jshs.2025.101097
  2. Ruiz JR, Butraqueño J. Add exercise to weight loss drugs for optimal metabolic health. BMJ. 2026;392. doi:10.1136/bmj.s571
  3. D’Souza AC, Lau KJ, Phillips SM. Exercise in the maintenance of weight loss: health benefits beyond lost weight on the scale. British Journal of Sports Medicine. 2021;56:771–772. doi:10.1136/bjsports-2021-104754
  4. Jensen S, Fiorenza M, Juhl C, et al. Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity. Sports Medicine (Auckland, N.Z.). 2026;56:1785–1800. doi:10.1007/s40279-025-02386-0
  5. Jensen S, Blond MB, Sandsdal RM, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine. 2024;69. doi:10.1016/j.eclinm.2024.102475
  6. Noronha JC, Van Gaal LV, Neeland I, et al. Optimizing GLP-1 therapies for obesity and diabetes management. Obesity Pillars. 2025;16. doi:10.1016/j.obpill.2025.100222
  7. American College of Sports Medicine. Sit Less, Move More, and Exercise: The Reasons Why. ACSM. Available at: https://acsm.org/sit-less-move-more-exercise-reasons-why/
  8. Piercy KL, Troiano RP, Ballard RM, et al. The Physical Activity Guidelines for Americans. JAMA. 2018;320(19):2020–2028. doi:10.1001/jama.2018.14854
  9. Sievenpiper J, Ard J, Blüher M, et al. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: An expert consensus statement using a modified Delphi approach. Obesity Pillars. 2025;17. doi:10.1016/j.obpill.2025.100228
  10. Szafraniec A, Korzeniowska A, Chmiela M, Jonderko L. Muscle Mass Preservation as a Therapeutic Challenge in GLP-1 Receptor Agonist Therapy. Quality in Sport. 2026. doi:10.12775/qs.2026.56.72375
  11. De Girolamo G, Sangineto M, Di Gioia G, Bianco R, Ciarnelli M, Serviddio G. Muscle health in the modern era of incretin-based therapies. European Journal of Clinical Investigation. 2025;56. doi:10.1111/eci.70155
  12. Chavez AM, Barria RC, León-Sanz M. Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary? Current Opinion in Clinical Nutrition and Metabolic Care. 2025;28:351–357. doi:10.1097/mco.0000000000001130
  13. Izquierdo M, Merchant R, Morley JE, et al. International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines. The Journal of Nutrition, Health & Aging. 2021;25:824–853. doi:10.1007/s12603-021-1665-8
  14. Berg S, Stickle H, Rose SJ, Nemec EC. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obesity Reviews. 2025;26. doi:10.1111/obr.13929
  15. Tzang C, Wu P, Luo C, et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine. 2025;90. doi:10.1016/j.eclinm.2025.103680
  16. Quarenghi M, Capelli S, Galligani G, Giana A, Preatoni G, Quarenghi RT. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies. Journal of Clinical Medicine. 2025;14. doi:10.3390/jcm14113791
  17. Fazio G. Comparative analysis of monthly weight-regain dynamics after discontinuation of semaglutide vs tirzepatide. Cardiovascular Research. 2026. doi:10.1093/cvr/cvag092.033
  18. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring, Md.). 2025;33:1475–1503. doi:10.1002/oby.24336
  19. Celletti F, Farrar J, De Regil LD. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. 2025. doi:10.1001/jama.2025.24288

This article is for informational and educational purposes only. It is not, nor is it intended to be substitute for professional medical advice, diagnosis, or treatment and should never be relied upon for specific medical advice.